• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Karyopharm Therapeutics Inc.

    10/30/25 3:18:07 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPTI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Karyopharm Therapeutics Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    48576U205

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    48576U205


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    49,414.00
    7Sole Dispositive Power

    355,817.00
    8Shared Dispositive Power

    52,405.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    408,222.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.70 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Karyopharm Therapeutics Inc
    (b)Address of issuer's principal executive offices:

    85 Wells Avenue, 2nd Floor, Newton, MA, 02459
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    48576U205
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    408222
    (b)Percent of class:

    4.7  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    49414

     (iii) Sole power to dispose or to direct the disposition of:

    355817

     (iv) Shared power to dispose or to direct the disposition of:

    52405

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:10/30/2025
    Get the next $KPTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KPTI

    DatePrice TargetRatingAnalyst
    10/13/2025$15.00Neutral → Buy
    H.C. Wainwright
    7/16/2025Buy → Neutral
    H.C. Wainwright
    7/11/2025$27.00Buy
    H.C. Wainwright
    1/19/2023$8.00Overweight
    Piper Sandler
    11/4/2022$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    3/8/2022$12.00 → $8.00Sector Perform
    RBC Capital
    3/2/2022$8.00 → $6.00Market Perform
    SVB Leerink
    2/9/2022$8.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $KPTI
    SEC Filings

    View All

    SEC Form S-3 filed by Karyopharm Therapeutics Inc.

    S-3 - Karyopharm Therapeutics Inc. (0001503802) (Filer)

    11/3/25 4:16:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Karyopharm Therapeutics Inc.

    S-3 - Karyopharm Therapeutics Inc. (0001503802) (Filer)

    11/3/25 4:13:16 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Karyopharm Therapeutics Inc.

    10-Q - Karyopharm Therapeutics Inc. (0001503802) (Filer)

    11/3/25 7:14:15 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 800 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of October 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecuti

    11/3/25 4:05:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

    – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million and U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $120 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third quarter ended September 30,

    11/3/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

    -- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 27, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2025 financial results on Monday, November 3, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, November 3, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyo

    10/27/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Abate Kristin was granted 12,799 shares, increasing direct ownership by 127% to 22,845 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    10/16/25 4:33:08 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Development Officer Poulton Stuart was granted 39,682 shares, increasing direct ownership by 143% to 67,392 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    10/16/25 4:32:04 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, General Counsel&Secretary Mano Michael was granted 43,650 shares, increasing direct ownership by 204% to 65,075 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    10/16/25 4:30:58 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Karyopharm Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Karyopharm Therapeutics from Neutral to Buy and set a new price target of $15.00

    10/13/25 8:40:25 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Karyopharm Therapeutics from Buy to Neutral

    7/16/25 7:54:08 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Karyopharm Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $27.00

    7/11/25 8:13:36 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Leadership Updates

    Live Leadership Updates

    View All

    Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

    NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow

    1/2/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

    NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs wi

    12/9/24 8:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

    NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t

    11/20/24 4:05:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Financials

    Live finance-specific insights

    View All

    Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

    – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million and U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $120 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third quarter ended September 30,

    11/3/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

    -- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 27, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2025 financial results on Monday, November 3, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, November 3, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyo

    10/27/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

    – New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product Revenue Guidance to $110 Million to $120 Million – – The Company is Exploring Financing Transactions and Strategic Alternatives to Extend its Cash Runway and Maximize Value – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Aug. 11, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc

    8/11/25 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/14/24 4:22:08 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/12/24 3:50:51 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/4/24 11:49:19 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care